Concepedia

Mitul Gandhi

MG

Statistics

Publications

12

Citations

815

H-Index

12

Active since

2013

Affiliations

Virginia Cancer Specialists(Current)

The University of Texas MD Anderson Cancer Center

Fred Hutch Cancer Center

Willamette Valley Cancer Institute and Research Center

Texas Oncology

Mitul Gandhi is an author at Virginia Cancer Specialists specializing in medicine, oncology, and cancer pharmacology.

Publications per year

2013–2024

12

Publications

12

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Adam M. Petrich, Mitul Gandhi, Borko Jovanovic et al. · Blood · 2014 · 466 citations

, , +9

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

Mazyar Shadman, Ian W. Flinn, Moshe Levy et al. · The Lancet Haematology · 2022 · 89 citations

, , +14

Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma

Daniel J. Landsburg, Adam M. Petrich, Jeremy S. Abramson et al. · Cancer · 2015 · 86 citations · Full text

, , +17

ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.

Daniel P. Petrylak, Meredith McKean, Joshua M. Lang et al. · Journal of Clinical Oncology · 2024 · 38 citations

, , +17

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Levy et al. · Blood · 2021 · 24 citations

, , +9

1–5 of 12